Cannabis Law and Access in Lesotho

Lesotho licensed commercial cannabis cultivation in 2017 , before Canada federally legalised, before most of Europe had a coherent medical framework, and well before Australia's Therapeutic Goods Administration had processed its first significant wave of prescriptions. That timing surprises most people I mention it to. A landlocked kingdom of roughly 2.2 million people, encircled entirely by South Africa, quietly became the first country on the African continent to issue licences for the legal cultivation of cannabis. Worth paying attention to.

A quick note before we go further: this article is about Lesotho's domestic legal framework. It has no bearing on Australian law. If you're an Australian reader curious about how cannabis is regulated here, that involves an entirely different set of instruments , the TGA, the Poisons Standard, and pathways like the Special Access Scheme and the Authorised Prescriber scheme. Those are separate conversations.

The 2017 licensing decision and what drove it

Lesotho's Ministry of Health issued the first cannabis cultivation licence in 2017 under the Drugs of Abuse Act 1973, using a ministerial amendment to carve out a licit pathway for licensed producers. The explicit policy rationale was economic: cannabis had been grown informally in the highlands for generations, and the government sought to capture revenue, attract foreign investment, and bring an existing informal industry into a regulated structure.

The geography matters here. Lesotho sits at altitude , much of the country is above 1,800 metres; which produces growing conditions that reportedly yield plants with distinctive cannabinoid and terpene profiles. Compounds like tetrahydrocannabinol (THC) and cannabidiol (CBD) accumulate in the resin of the cannabis plant, and altitude, UV exposure, and temperature fluctuation all influence that accumulation, though the precise agronomic relationships are still being studied.

The initial licences were explicitly for export, specifically targeting the pharmaceutical and medical cannabis markets in Europe and beyond. Domestic medical use was a secondary consideration in those early instruments.

The Drugs of Abuse Act and licensing structure

The foundational legislation is the Drugs of Abuse Act 1973, which classifies cannabis as a prohibited substance in its base form. The ministerial licensing regime creates a formal exemption for licensed holders, essentially the same structural logic you see in many other jurisdictions: the substance remains controlled, but a permit/licence pathway exists for authorised activity.

Licences are issued by the Ministry of Health and cover cultivation, processing, and export. There are separate licence categories, and applicants must satisfy requirements around security, record-keeping, and good manufacturing practice. The term GMP appears in Lesotho's licensing documents in the context of export readiness; if you're supplying a European market, for instance, EU-GMP compliance becomes a practical prerequisite regardless of what Lesotho's own rules say. You can read more about what Good Manufacturing Practice means in a cannabis context in our glossary.

Licence fees are substantial relative to the local economy, which has drawn criticism. Small farmers, the people who have grown cannabis in the highlands for decades, have generally been unable to access the formal licence pathway. The capital requirements effectively concentrated early licences among better-resourced operators, many of them international investors. That tension between a liberalisation policy and who actually benefits from it is something I find genuinely difficult to set aside when describing this framework as a success story.

Personal cultivation and recreational use: still prohibited

Here's where Lesotho's framework diverges sharply from, say, Canada's or parts of the United States. Personal cultivation and recreational use remain illegal under the Drugs of Abuse Act. The licensing regime is commercial and medical, not a decriminalisation or legalisation of personal use. Penalties for unlicensed possession and cultivation remain on the books.

This distinction matters a great deal. Several commentators in 2017 and 2018 characterised Lesotho as having "legalised cannabis," which was imprecise at best. What happened was the creation of a licensed commercial pathway within an otherwise prohibitive framework. The informal subsistence farmers who had been growing in the highlands were not automatically brought inside that framework; they were still technically in breach of the law, just as they had been before.

Domestic medical access

Lesotho's domestic medical cannabis programme exists but is not well documented in the peer-reviewed literature. The Ministry of Health has issued provisions for medical access, with cannabis-derived products theoretically available via prescription. The practical implementation, how prescriptions are issued, which products are available domestically, what the dispensing infrastructure looks like, is far less clear than the export licensing framework.

For context: understanding why cannabinoids interact with human physiology at all requires some grounding in the endocannabinoid system, the receptor network that includes CB1 receptors (expressed heavily in the central nervous system) and CB2 receptors (more prevalent in immune tissue). That system is not unique to humans or to cannabis; it's a conserved biological feature across most vertebrates. The pharmacology of cannabinoids is real, which is why regulatory frameworks; including Lesotho's, have carved out medical pathways rather than treating cannabis as simply recreational.

The broader African context

Lesotho's 2017 move preceded a wave of African regulatory activity. Zimbabwe licensed medical cannabis in 2018. South Africa's Constitutional Court decriminalised private personal use and cultivation in September 2018, in a judgment (Prince v Minister of Justice) that has since shaped ongoing legislative debate. Zambia, Malawi, and Rwanda have all taken steps toward medical or industrial hemp frameworks.

I spent part of last winter going back through some of the early WHO pre-review documents on cannabis scheduling, this was while I was pulling together some notes on comparative frameworks, cup of tea going cold, Trevor (my sourdough starter) bubbling away on the bench; and what struck me was how consistent the tension is across jurisdictions: the pharmacological evidence is running well ahead of most regulatory structures, and countries are retrofitting legal instruments not originally designed for a nuanced cannabis framework.

Lesotho's position is partly that of a first-mover on the continent and partly a cautionary example. The licensing model attracted foreign capital but arguably didn't distribute economic benefit as broadly as the initial policy framing implied.

What Australian readers should understand

Australian law has no reciprocal recognition of overseas cannabis licences or frameworks. A product legally produced in Lesotho under its licensing regime would still need to satisfy Australian import requirements, TGA registration or approval pathways, and scheduling under the Poisons Standard before it could be supplied here. Cannabis products containing THC above specified thresholds are Schedule 8 (controlled drug) in Australia, you can read about what Schedule 8 classification means in practice, and how it differs from Schedule 4 prescription-only status, in our glossary entries.

CBD products in Australia below 150mg/day with low THC content were rescheduled to Schedule 3 (pharmacist-only) in 2021, but that's a domestic rescheduling decision, not an importation free pass. The ARTG, the Australian Register of Therapeutic Goods; remains the relevant instrument for what can be legally supplied here.

Lesotho's story is worth following because it represents one model of how a developing economy can attempt to build a regulated cannabis industry from an existing informal agricultural base. Whether that model has served its intended beneficiaries as well as it served early investors is a fair question, and the answer so far seems to be: not entirely.

The regulatory architecture of any licit cannabis market, here, in Lesotho, or anywhere else, is built on top of the same underlying pharmacology. Cannabinoids, the endocannabinoid system, and the plant's complex mixture of terpenes and minor cannabinoids don't change depending on which side of a border you're standing on. The law does. And the law, frankly, is always the part that needs the most careful reading.

Sources

• WHO Expert Committee on Drug Dependence; Cannabis Pre-Review Report, World Health Organisation
• Cannabis Drug Trafficking and Legal Frameworks, United Nations Office on Drugs and Crime
• Medicinal Cannabis Guidance Documents; Therapeutic Goods Administration (Australia)
• Cannabis Policy in Africa, A Review of Regulatory Developments, NCBI / PubMed

, Marcus Hale, Regulatory researcher; TGA & access law